Aims/hypothesis Protein tyrosine phosphatase non-receptor 22 (PTPN22) plays a central role in T cell, B cell and innate immune cell signalling. A genetic variation in Ptpn22 is considered a major risk factor for the development of type 1 diabetes and has been the subject of extensive study. While several reports have addressed how Ptpn22 might predispose to autoimmunity, its involvement in other immune-mediated diseases, such as allograft rejection, has not been explored. Methods To address a possible function for Ptpn22 in allograft rejection, we used a mouse model of pancreatic islet transplantation. We performed transplant tolerance experiments and determined how PTPN22 shapes tolerance induction and maintenance.
alloreactive T cells after allogeneic pancreatic islet transplantation compared with wild-type (WT) mice, but reject grafts with similar kinetics. This is not only due to their well-documented increase in forkhead box protein P3 (FOXP3) + T regulatory (Treg) cells but also to the expansion of T regulatory type 1 (Tr1) cells caused by the lack of PTPN22. In addition, a tolerogenic treatment known to induce transplant tolerance in WT mice via Tr1 cell generation is more effective in Ptpn22 −/− mice as a conse- 
Introduction
The autoimmune predisposing gene Ptpn22 is involved in several aspects of immune regulation [1] [2] [3] [4] . Ptpn22 encodes a protein tyrosine phosphatase involved in T cell receptor (TCR) [5] [6] [7] [8] , B cell receptor [9] [10] [11] and innate immune signalling [12] . A strong link between the R620W genetic variant of Ptpn22 and the development of autoimmunity was made a decade ago [13] [14] [15] . Since then, healthy donors and patients, carriers of PTPN22*W, and genetically modified mice have been studied, with contradictory results reported. Some studies have suggested that PTPN22*W is a loss of function variant associated with increased T cell signalling [16] , while others have suggested the opposite, i.e. that the polymorphism increases phosphatase activity, resulting in reduced T cell activation [17, 18] . Of the several mouse models that have served to address the role of protein tyrosine phosphatase non-receptor 22 (PTPN22), two Ptpn22 knockout (Ptpn22 −/− ) mouse lines were reported that, despite having increased numbers of memory T cells, spontaneous germinal centres and elevated serum immunoglobulin concentrations compared with wild-type (WT) mice, showed no signs of autoimmunity [7, 19] . However, when crossed with another tyrosine phosphatase mutant mouse model, the CD45 E613R, Ptpn22 −/− mice developed lupus-like disease [20] .
Ptpn22
−/− mice contained an increased proportion and greater absolute number of forkhead box protein P3 (FOXP3) + T regulatory (Treg) cells [19, 21] , and Treg cell transfer from Ptpn22 −/− mice controlled experimental colitis [19] . Ptpn22 −/− mice were resistant to experimental autoimmune encephalomyelitis [21] but more susceptible to dextran sulphate induced colitis [12, 22] and experimental arthritis [23] . NOD mice with knocked down expression of PTPN22 by RNA interference [24] or, in contrast, with transgenic overexpression of PTPN22 [25] were protected from type 1 diabetes mellitus. These results indicate that PTPN22 can promote or hinder tolerance depending on the experimental setting, which possibly depends on the type of effector cells that promote inflammation [3] . Various types of peripherally derived T regulatory (pTreg) cells have been described. The best characterised subsets are the FOXP3 + pTreg and T regulatory type 1 (Tr1) cells [26, 27] . Tr1 cells are characterised by their high expression of IL-10 and lack of constitutively expressed FOXP3, and can be identified by surface expression of lymphocyte activation gene 3 (LAG-3) and CD49b [28, 29] . It is not known whether PTPN22 is involved in the induction, maintenance and function of Tr1 cells. Given that PTPN22 controls FOXP3 + Treg cell peripheral induction and level of IL-10 production [19] , we investigated the role of PTPN22 in allograft rejection and Tr1 cell mediated transplant tolerance using a mouse model of pancreatic islet transplantation.
Methods
Mice BALB/c, C3H and C57BL/6 mice were purchased from Charles River (Calco, Italy). Homozygous Ptpn22-deficient mice were previously described [7] . WT and Ptpn22 −/− littermates were used throughout the study. All animals were housed under specific pathogen free conditions in compliance with guidelines of the San Raffaele Institutional Animal Care and Use Committee (IACUC number: 479).
Islet transplantation and treatments Pancreatic islets from BALB/c or C3H donors were transplanted under the kidney capsule of chemically (streptozotocin) induced diabetic recipient mice, as previously described [30] . /recipient) from the spleens of TxT or UM mice were subjected to FACS or beadpurification (CD4-negative isolation followed by LAG-3-phycoerythrin (PE) staining and anti-PE microbead isolation, Miltenyi Biotec, San Diego, CA, USA) prior to adoptive transfer into recipients 1 day before transplantation. In ELIspot experiments, T cells were positively purified with CD90.2 microbeads (Miltenyi Biotec), whereas T celldepleted splenocytes (TDS) were prepared by depletion with CD90.2 microbeads. TDS from C57BL/6, C3H or BALB/c mice were irradiated at 3,000 rads before co-culture.
ELIspot immunoassay ELIspot for IFN-γ (BD Pharmingen) was performed as previously described [32] . Briefly, 96-well millititre HA plates (Millipore, Bedford, MA, USA) were coated with 5 μg/ml IFN-γ capture antibody. After a 10% (vol./vol.) FBS/RPMI blocking step, CD90.2-purified T cells from the spleens of tolerant mice were plated at 2×10 5 /well and cultured for 3 days in the presence of an equal number of C57BL/6, BALB/c or C3H (third donor control) irradiated TDS. Plates scanned and spots representing cytokineproducing cells were counted using an Eli.Expert ELIspot Reader and analysed using Eli.Analyze software version 5.1 (A.EL.VIS, Cologne, Germany).
Statistical analysis
Comparisons between groups were performed using the unpaired, two-tailed Student's t test or the Mann-Whitney nonparametric U test, whereas the KruskalWallis test was used for multiple comparisons. Islet allograft survival was determined by Kaplan-Meier survival curves and compared using the logrank test. Prism software (GraphPad, USA) was used for all analyses. Statistical significance is indicated by *p<0.05, **p<0.01 and ***p<0.001.
Results

Blockade of Treg cell function accelerates islet allograft rejection in WT but less so in Ptpn22
−/− mice In the steady state, [21] . CD4 single positive, CD4/ CD8 double negative and double positive, and positive selection stages (defined by CD69 and TCRβ) were moderately but significantly altered by the absence of PTPN22 (ESM Fig. 1 ).
An increased number of splenocytes and increased frequency of memory T cells were detected in Ptpn22 −/− mice in the steady state (ESM Fig. 2 and data not shown), as previously described [7] . Frequencies of memory CD4 + T cells (i.e. CD44 
CD4
+ and CD8 + T cells was lower in Ptpn22 −/− mice in the steady state (ESM Fig. 2) . However, the ratio of naive to memory T cells was not maintained at WT levels in the absence of PTPN22 (ESM Fig. 2 ). The number of IFN-γ-producing BALB/c-specific T cells was significantly increased in Ptpn22 −/− Tx mice (Fig. 1d, e) , suggesting that a lack of PTPN22 favours the generation of alloreactive T cells. The kinetics of pancreatic islet graft rejection between Ptpn22 −/− and WT mice was similar (BALB/c → WT vs
; Fig. 1f ). Given that the increased number of allogeneic T cells in Ptpn22 −/− mice might be compensated for by the enlarged number of Treg cells, P60 (a peptide that specifically blocks FOXP3) was administered [33] . WT P60-treated Tx mice rejected grafts much faster than untreated Tx mice; however, P60 treatment did not accelerate graft rejection to similar levels in Ptpn22 −/− mice ( Fig. 1f and Table 1 ).
These results show that FOXP3 blockade is less effective in accelerating graft rejection in Ptpn22 −/− mice, thus suggesting that additional regulatory mechanisms might be active in the absence of PTPN22. Fig. 3 ). To address whether Tr1 cells are involved in allograft rejection in Ptpn22 −/− mice, LAG-3 was blocked by mAb administration [34] . Anti-LAG-3 mAb treatment significantly accelerated islet allograft rejection in Ptpn22 −/− Tx mice, and had a similar effect in WT Tx mice (Fig. 2e , f and Table 2 ). Combined anti-LAG-3 mAb and FOXP3 blockade also accelerated graft rejection; however, this did not occur faster than with anti-LAG-3 mAb alone (Fig. 2e , f and Table 2 ). Since LAG-3 can be also expressed by a subset of pTreg cells, its expression was 
G-CSF/RAPA treatment in Ptpn22
−/− mice induces transplant tolerance that is maintained after Treg depletion or blockade We previously described an efficient immunemodulatory protocol that combines G-CSF/RAPA and leads to pancreatic islet transplant tolerance in WT mice via Tr1 cells [30] . Thus, this experimental model was used to evaluate the role of PTPN22 in Tr1 cell mediated transplant tolerance. G-CSF/RAPA treatment led to stable long-term transplant tolerance in 100% of Tx mice (Fig. 3a) . A higher frequency of memory phenotype CD4 + and CD8 + T cells was found in the spleen but not in kidney draining lymph nodes (dLNs) or the grafts of Ptpn22 −/− TxT mice (Fig. 3b-f ). Given that memory T cell numbers were increased in the spleens of Ptpn22 −/− mice in the steady state (ESM Fig. 2 ), the fold change was calculated. Lack of PTPN22 did not affect the expansion of splenic memory CD4 + and central memory CD8 + T cells (shown in Fig. 3c, e, f) . However, effector memory CD8 + splenocytes showed a greater expansion in Ptpn22 −/− TxT mice (Fig. 3e ).
Treg cells were found at a higher frequency in the spleens and kidney dLNs but not in the grafts of Ptpn22 −/− TxT mice ( Fig. 4a-c) . Splenic Treg cells expansion was similar in WT and Ptpn22 −/− TxT mice (on average, by 1.5 times compared + Treg cells by approximately 60% in WT TxT mice 10 days after treatment (ESM Fig. 5 ), in line with previous reports [35] . None of the treatments modified G-CSF/RAPA-induced transplant tolerance in Ptpn22 −/− mice (Fig. 4e, f) , similar to our previous data in WT mice [30] . Thus, G-CSF/RAPA treatment induces transplant tolerance in Ptpn22 −/− mice, which is maintained upon Treg cell depletion or blockade. and IL-10-producing CD4 + T cells were found at higher frequencies in the spleens of Ptpn22 −/− TxT mice, but were present at similar frequencies in kidney dLNs and were almost undetectable in the graft of both WT and Ptpn22 −/− TxT mice (Fig. 5a-c, ESM Fig. 3 and data not shown). A 3.5-fold Tr1 cell expansion, which is much greater than the amount of Treg cell expansion, was observed in the spleen of TxT mice. However, a lack of PTPN22 had no effect on the expansion or induction of Tr1 cells (Fig. 5b) . TxT mice also delayed allograft rejection (Fig. 5d) . CD4 + LAG-3 + T cells from Ptpn22 −/− TxT mice controlled allograft rejection in an antigen-specific manner, since recipients of islets from an irrelevant donor (i.e. C3H→C57BL/6) rejected the graft (Fig. 5e ). CD4 + LAG-3 + T cells isolated from UM Ptpn22 −/− mice did not confer protection from graft rejection ( Fig. 5f ), demonstrating that CD4 (Fig. 6a) , thus confirming the importance of the spleen in this transplant tolerance model [30, 31] . Next, the requirement for Tr1 cells in maintaining transplant tolerance in Ptpn22
−/− mice was tested by administering an anti-LAG-3 mAb. Whereas anti-LAG-3 mAb treatment inhibited transplant tolerance in WT TxT mice, Ptpn22
TxT mice remained tolerant (Fig. 6b) . Simultaneous P60 peptide and anti-LAG-3 mAb administration inhibited transplant tolerance in Ptpn22 −/− TxT mice and accelerated graft rejection in WT TxT mice (Fig. 6b, c) . These results show that both Tr1 and Treg cells mediate transplant tolerance in Ptpn22 (Fig. 6d , e and data not shown) compared with those of WT TxT mice, suggesting they have increased function, in agreement with previous reports [19] . In conclusion, a lack of PTPN22 further stabilises G-CSF/RAPA-mediated transplant tolerance by promoting FOXP3 + Treg and Tr1 cells that act in synergy in vivo.
Discussion
A genetic variation affecting PTPN22 (R620W) is one of the major non-HLA genetic risk factors for autoimmunity. Whereas several mouse and human studies have shown that PTPN22*W increases adaptive and dampens innate immune responses [1, 2] , it remains unclear how it predisposes to autoimmunity. Here, we show in a mouse model of pancreatic RAPA develop robust transplant tolerance, which is maintained via both Tr1 and Treg cells. This contrasts with WT mice, in which mainly Tr1 cells sustain transplant tolerance after the same tolerogenic treatment [30] . These data show that a lack of PTPN22 strengthens transplant tolerance in mice and suggests that PTPN22 may serve to therapeutically target Treg and Tr1 cells. The resistance of Ptpn22 −/− mice to develop spontaneous autoimmunity despite heightened lymphoproliferation and abnormal expansion of memory T cells was attributed to the enhanced development of FOXP3 + Treg cells [19, 21] . We found increased Treg cell thymic development in the absence of PTPN22, similar to a previous study [21] in which the same knockout mouse line was used. This contrasts with another study in which different knockout mice were used and no difference in Treg thymic development was seen [19] . The reasons for this discrepancy are unclear.
Our study provides new data supporting the hypothesis that Tr1 cells expand in Ptpn22 −/− mice and might have an ancillary function in protection from autoimmunity. The mechanism by which PTPN22 controls the number and function of Tr1 and Treg cells is not completely understood. It is possible that PTPN22 controls Tr1 and Treg development by modulating the threshold of T cell activation, as originally suggested [7] . Alternatively, it may act by modulating the number, tissue distribution and function of professional antigenpresenting cells (APCs), known to play a key role in Treg cell development and function [36] [37] [38] . We previously showed that whereas PTPN22 sets the threshold of Treg cell conversion in vitro, it affects the accumulation/survival, and to a lesser extent the differentiation, of Treg cells in vivo [39] . In the present study, Treg and Tr1 cell numbers were already increased in the spleens of Ptpn22 Treg cells were found at a higher frequency in the spleen and in kidney dLNs of Ptpn22 −/− TxT mice than of WT TxT mice, but were present at similar levels in the graft. In contrast, Tr1 cells were found at a higher frequency in the spleens of Ptpn22 −/− TxT mice than of WT TxT mice, while their frequency was similar in kidney dLNs and they were almost absent from the graft. These data confirm our previous observations by showing that transplant tolerance induced via G-CSF/RAPA treatment is maintained in WT mice by Tr1 cells that predominantly reside in the spleen [30, 31] . However, transplant tolerance in Ptpn22 −/− mice is maintained by both
Tr1 and Treg cells that act in both the spleen and kidney dLNs. Treg and Tr1 cells suppress target cells via various mechanisms, some of which are shared, e.g. the killing or modulation of APCs and the production of IL-10 [40] . A previous study showed that Ptpn22 −/− Treg cells produce increased amounts of IL-10 in the steady state compared with WT cells and have enhanced adhesive properties due to increased levels of LFA-1 [19] . We found that Ptpn22 Taken together, our data show that PTPN22 plays a key role in Treg and Tr1 cell generation, with important implications for transplant tolerance. Lack of PTPN22 enhances the number of Treg and Tr1 cells in the steady state and strengthens transplant tolerance by increasing the regulatory properties of Treg cells. Treg and Tr1 cells in tolerant mice migrate to different sites, as we previously showed [31] , and act synergistically or operate via overlapping mechanisms. Together, these findings suggest that PTPN22 can serve to therapeutically target Treg and Tr1 cells to moderate immune responses toward allografts.
